TD Cowen analyst Joseph Thome has maintained their bullish stance on RAPP stock, giving a Buy rating today.
Joseph Thome has given his Buy rating due to a combination of factors that highlight the potential of Rapport Therapeutics, Inc.’s lead program, RAP-219. The company is making significant strides in its clinical trials, with the key Phase IIa readout for RAP-219 in focal onset seizures expected next quarter. This trial, which uses a novel design, has received praise from key opinion leaders, although investor sentiment has been more cautious. To address this, Rapport Therapeutics plans to host an investor day to provide further insights into the trial’s progress and expectations.
Additionally, the company’s recent studies have confirmed RAP-219’s target engagement and tolerability, which are crucial for its development in treating both focal epilepsy and bipolar mania. The initiation of a Phase IIa trial for bipolar mania is scheduled for the next quarter, with data anticipated in the first half of 2027. These developments, along with the promising preclinical data and the potential efficacy of RAP-219, contribute to Thome’s optimistic outlook and Buy rating for the company’s stock.
In another report released today, JonesTrading also reiterated a Buy rating on the stock with a $42.00 price target.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RAPP in relation to earlier this year.